肾功能监测对动脉灌注化疗的安全意义临床研究

Clinical Study on Safety Significance of Renal Function Monitoring for Arterial Infusion Chemotherapy

目的:本研究旨在研究肾功能监测对动脉灌注化疗的临床安全意义。方法:对120例确诊肝癌、肺癌、盆腔部癌并符合行动脉灌注化疗的患者,于动脉灌注化疗前及灌注化疗14d内,隔日查尿常规、尿N-乙酰-β-D-葡萄糖苷酶(N-acetyl-β-D-glucosam inidase,NAG)、γ-谷氨酰转酞酶(gamma-glutamyltransferase,γ-GT),化疗第7天及第14天查血肌酐及血尿素氮。分析比较前后结果。结果:120例患者中,有99例(82.50%)在化疗前各项检查指标均正常,21例(17.50%)化疗前有1项或2项指标异常,多为尿NAG、γ-GT增高;而化疗后各项指标正常者仅22(18.33%)例,98例(81.67%)有1项或多项指标异常,相关指标多在灌注化疗第3-4天明显增高,2周左右仍有部分未降至正常水平。前后对比分析均p<0.001.结论:动脉灌注化疗对患者肾功能仍有影响,实行两周的肾功能监测对患者的安全具有临床意义。

Objective： To study the clinical safety significance of renal function monitoring for arterial chemotherapy. Method： Before and 14 days within arterial chemotherapy infusion, 120 cases with liver canc- er, lung cancer and pelvic cancer respectively, checked the urine routine, urine N-aeetyl-β-D-glucose glycoside enzyme （ N-aeetyl-β-D-glueosaminidase, NAG） , γ-glutamyl-GT （ gamma-glutamyltransferase, γ-GT） once every two days, and serum creatinine and blood urea nitrogen on the 7th days and 14th days. Result： The indicators in 120 cases, before chemotherapy, there were normal in 99 cases （82.50%） , 21 cases （17.50%） were 1 or 2 abnormal, urinary NAG, γ-GT increased for more. But after chemotherapy only 22 （ 18.33% ） cases were normal, 98 cases （81.67%） were one or more abnormal, more relevant in- dicators chemotherapy significantly increased on the third or fourth day, 2 weeks still failed to normal levels. p 〈0.001 for comparative analysis. Conclusion： Renal function was affected for patients with arterial infu- sion chemotherapy, and there were clinic al safety significance of monitoring renal function for two weeks.